NEBULA Respiratory Multi-Omics Database
Transforming respiratory biology into intelligence for drug discovery.
The dataset respiratory discovery has been missing
NEBULA is Diag‑Nose’s in‑development nasal multi‑omics database, built to power respiratory biomarker discovery and drug development.
Helps research and pharma partners discover and validate novel biomarkers, identify disease subtypes, and understand disease and treatment-response biology by linking longitudinal nasal biomarker data to clinical outcomes.
Every dataset is collected using ABEL, our standardised nasal sampling method, so data stays comparable across studies and sites.
Supports partners to evaluate and de-risk pharmaceutical assets, train and validate biological models, and design smarter clinical trials and patient stratification strategies - generating new diagnostic and therapeutic hypotheses along the way.
NEBULA grows with every patient enrolled, building breadth and depth across respiratory indications over time.
From data to discovery
Identify novel targets
NEBULA aims to reveal molecular patterns associated with disease progression and therapeutic response, providing researchers with new starting points for target discovery.
Optimise candidate selection
By linking biomarker data to clinical outcomes, NEBULA aims to help pharma partners prioritise candidates for further investigation using biologically informed evidence.
Power validation & hypotheses
Built on longitudinal, clinically-linked data collected through a single standardised method, NEBULA gives pharma, biotech and research partners a foundation that grows more powerful with every study, enabling biomarker validation, hypothesis testing, and analytical models that fragmented or multi-source datasets simply cannot support.
Curated, longitudinal, clinically linked
Data · From company overview
- Curated, longitudinal nasal multi-omics data
- Linked to clinical metadata and treatment history
- Organised by study and indication
- Built on standardised ABEL collection
- Grows cumulatively with every enrolled patient
Secure, privacy-governed access
Partners access NEBULA through secure, privacy‑governed agreements.
The platform is being built to the compliance and governance standards that pharmaceutical and institutional research partnerships require.
Includes access controls, audit trails, and partner confidentiality protections, ensuring one partner’s queries and insights remain their own.
Designed to scale with partner needs, providing a discovery resource no single organisation could build independently.
.svg)
Pilot to launch
Data · Roadmap
In progress
Phase 01
Pilot access
Early access for partners.
2026
Planned
Phase 02
Launch
General availability.
2027
Respiratory conditions in the dataset
Asthma
Chronic rhinosinusitis
COPD
Rhinitis
Infectious airway disease
Non-infectious lung disease
Common questions
Common questions
What is NEBULA?
What does it contain?
What does NEBULA aim to enable?
How do partners access it?
Who is NEBULA for?
When is it available?
Nebula is an investigational technology. It has not been approved by the FDA or any other regulatory authority for diagnostic or clinical use.
RhinoMAP is an investigational technology. It has not been approved by the FDA or any other regulatory authority for diagnostic or clinical use.
RhinoMAP is an investigational technology. It has not been approved by the FDA or any other regulatory authority for diagnostic or clinical use.